In a hospitalized patient with hypertension on amlodipine and hydrochlorothiazide who was started on lithium extended‑release 450 mg nightly, how should the antihypertensive regimen be adjusted and what baseline renal function, electrolyte, and lithium monitoring is recommended?

Discontinue HCTZ immediately and replace with an alternative antihypertensive agent due to the significant drug interaction with lithium that increases lithium toxicity risk.

Critical Drug Interaction: HCTZ and Lithium

The concurrent use of hydrochlorothiazide with lithium is contraindicated or requires extreme caution. Thiazide diuretics reduce renal lithium clearance by 25-40% and substantially increase the risk of lithium toxicity 1, 2. The FDA label explicitly states that "lithium generally should not be given with diuretics" as they "reduce the renal clearance of lithium and greatly increase the risk of lithium toxicity" 1.

Immediate Management Steps:

1. Discontinue HCTZ 25 mg daily now

• The interaction risk outweighs any BP benefit
• Thiazide diuretics are particularly problematic with lithium compared to other antihypertensive classes 2

2. Replace with increased amlodipine dosing

• Increase amlodipine from 5 mg to 10 mg daily 3
• Amlodipine has no significant interaction with lithium and maintains electrolyte balance 4
• This addresses the current BP readings of 149-151 systolic while avoiding the lithium interaction

3. If BP remains uncontrolled after amlodipine uptitration, add an ACE inhibitor or ARB

• Per 2024 ESC guidelines, the preferred combination is a RAS blocker (ACE-I/ARB) with a dihydropyridine CCB 5
• Caution: ACE inhibitors and ARBs also reduce lithium clearance, though less dramatically than thiazides 2
• If adding a RAS blocker, increase lithium monitoring frequency to weekly initially

Baseline Laboratory Monitoring Required

Before continuing lithium therapy, obtain:

• Serum creatinine and eGFR (baseline renal function)
• Serum electrolytes (sodium, potassium, chloride, bicarbonate)
• Serum lithium level (12-hour trough level, drawn immediately before next dose) 6
• Calcium and TSH (lithium can cause hypercalcemia and thyroid dysfunction)

The lithium therapeutic range is 0.6-1.2 mEq/L for maintenance therapy 6. However, with the recent HCTZ exposure, the patient may already have elevated lithium levels requiring dose adjustment.

Ongoing Lithium Monitoring Protocol

During acute stabilization (first 3 months):

• Lithium levels every 1-2 weeks until stable 6, 7
• Serum creatinine/eGFR monthly
• Electrolytes every 2 weeks initially, then monthly

Long-term maintenance:

• Lithium levels every 2-3 months 6, 8
• Serum creatinine/eGFR every 3 months 7, 8
• Monitor for polyuria/polydipsia (early sign of nephrogenic diabetes insipidus)

Red flags requiring nephrology consultation:

• eGFR decline >25% from baseline or rapid decline
• eGFR <45 mL/min/1.73m² 8
• eGFR <30 mL/min/1.73m² requires serious consideration of lithium discontinuation 7, 9

Blood Pressure Management Strategy

Current BP status:

• Readings of 149-151/60-64 mmHg represent Grade 1 hypertension
• Target BP per 2024 ESC guidelines: 120-129 mmHg systolic 5
• Patient reports baseline home BP in 120s, suggesting current elevations may be stress-related

Recommended approach:

1. Discontinue HCTZ immediately
2. Increase amlodipine to 10 mg daily (maximum dose, well-tolerated) 3
3. Continue BP monitoring every 4-6 hours during hospitalization
4. Address psychosocial stressors (housing/eviction concerns contributing to BP elevation)
5. If BP remains >140/90 after 7-14 days, add low-dose ACE inhibitor or ARB with increased lithium monitoring 5

Critical Pitfalls to Avoid

Do not:

• Continue HCTZ with lithium therapy—the interaction risk is too high
• Use loop diuretics as HCTZ replacement—they also increase lithium toxicity risk
• Add NSAIDs for any reason—they reduce lithium clearance and worsen renal function 1, 2
• Rely solely on lithium levels without monitoring renal function—nephrotoxicity can occur even with therapeutic levels 7, 9

The patient's low-normal heart rate (53-60 bpm) is acceptable given he reports this as his baseline and remains asymptomatic. Beta-blockers are not indicated and would be problematic given his bradycardia.

Risk-Benefit Consideration

While lithium carries renal risks, it remains the gold standard for bipolar disorder with robust evidence for suicide prevention and mood stabilization 7, 9. The key is eliminating modifiable risk factors—particularly the HCTZ interaction—while maintaining close monitoring. Duration of lithium therapy and episodes of toxicity are the primary risk factors for chronic kidney disease 10, 7, 9, making prevention of toxicity through appropriate drug selection paramount.